Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Kymera Therapeutics (NASDAQ: KYMR) will report third quarter 2025 financial results on November 4, 2025.
The company will host a video conference call and livestreamed webcast on November 4, 2025 at 8:30 a.m. ET. Investors can register to join the video call or view the webcast via the company’s Investors > News and Events page at www.kymeratx.com. A replay of the webcast will be archived and available after the event.
Kymera Therapeutics (NASDAQ: KYMR) riporterà risultati finanziari del terzo trimestre 2025 il 4 novembre 2025.
L'azienda terrà una videoconferenza e una webcast trasmessa in diretta il 4 novembre 2025 alle 8:30 ET. Gli investitori possono registrarsi per partecipare alla videoconferenza o guardare la webcast tramite la pagina Investitori > Notizie ed Eventi dell'azienda su www.kymeratx.com. Una riproduzione della webcast sarà archiviata e disponibile dopo l'evento.
Kymera Therapeutics (NASDAQ: KYMR) reportará los resultados financieros del tercer trimestre de 2025 el 4 de noviembre de 2025.
La empresa organizará una videoconferencia y una transmisión web en directo el 4 de noviembre de 2025 a las 8:30 a.m. ET. Los inversionistas pueden registrarse para unirse a la videollamada o ver la transmisión web a través de la página de Inversores > Noticias y Eventos de la empresa en www.kymeratx.com. Una repetición de la transmisión web se almacenará y estará disponible después del evento.
Kymera Therapeutics (NASDAQ: KYMR)는 2025년 11월 4일에 2025년 3분기 재무 실적을 발표할 예정입니다.
회사는 2025년 11월 4일 동부 표준시 기준 8:30 a.m. ET에 영상 컨퍼런스 콜과 라이브 스트리밍 웹캐스트를 개최합니다. 투자자들은 회사의 Investors > News and Events 페이지의 www.kymeratx.com에서 비디오 콜에 참여하거나 웹캐스트를 시청하기 위해 등록할 수 있습니다. 웹캐스트의 재생본은 이벤트 후에 보관되어 이용 가능합니다.
Kymera Therapeutics (NASDAQ: KYMR) publiera les résultats financiers du troisième trimestre 2025 le 4 novembre 2025.
L'entreprise organisera une conférence téléphonique et une webdiffusion en direct le 4 novembre 2025 à 8 h 30 (ET). Les investisseurs peuvent s'inscrire pour participer à l'appel vidéo ou visionner la webdiffusion via la page Investisseurs > Actualités et Événements de l'entreprise sur www.kymeratx.com. Une répétition de la webdiffusion sera archivée et disponible après l'événement.
Kymera Therapeutics (NASDAQ: KYMR) wird die Finanzergebnisse des dritten Quartals 2025 am 4. November 2025 bekannt geben.
Das Unternehmen wird am 4. November 2025 um 8:30 Uhr ET eine Videokonferenz und einen live gestreamten Webcast abhalten. Investoren können sich registrieren, um an der Videokonferenz teilzunehmen oder den Webcast über die Seite Investors > News and Events des Unternehmens unter www.kymeratx.com zu sehen. Eine Wiederholung des Webcasts wird archiviert und nach der Veranstaltung verfügbar sein.
Kymera Therapeutics (NASDAQ: KYMR) ستعلن عن النتائج المالية للربع الثالث من عام 2025 في 4 نوفمبر 2025.
ستستضيف الشركة مكالمة مؤتمرات بالفيديو وبث ويب حي في 4 نوفمبر 2025 الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة. يمكن للمستثمرين التسجيل للانضمام إلى المكالمة المرئية أو مشاهدة البث عبر صفحة المستثمرين > الأخبار والأحداث للشركة على www.kymeratx.com. سيتم حفظ نسخة من البث وسيكون متاحاً بعد الحدث.
Kymera Therapeutics (NASDAQ: KYMR) 将在 2025 年 11 月 4 日公布 2025 年第三季度财务结果。
公司将于 2025 年 11 月 4 日日举行视频电话会议和现场网络广播，时间为美东时间 8:30 a.m.。投资者可以通过公司投资者 > 新闻与活动页面在 www.kymeratx.com 注册参加视频电话会议或观看网络广播。网络广播的重播将被存档，活动结束后可用。
- None.
- None.
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
| Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300 |
FAQ
When will Kymera Therapeutics (KYMR) report third quarter 2025 results?
What time is the Kymera (KYMR) Q3 2025 conference call and webcast?
How can investors join the Kymera (KYMR) webcast on November 4, 2025?
Will a replay of the Kymera (KYMR) Q3 2025 webcast be available after the event?
Where can I find registration and the replay for Kymera (KYMR) Q3 2025 results?
